Novartis completes acquisition of Regulus Therapeutics

‼️Breaking News‼️

@novartis.bsky.social completed acquisition of Regulus Therapeutics, advancing #farabursen an investigational therapy targeting microRNA‑17 to slow cyst growth in #ADPKD

🔗 www.novartis.com/news/media-r...

Regulus Therapeutics Awarded Acquisition by Novartis Following Positive Drug Trial Results Regulus Therapeutics has secured an agreement with Novartis valued at $1.7 billion, as they report promising Phase 1b results for their ADPKD drug, farabursen.

Regulus Therapeutics Awarded Acquisition by Novartis Following Positive Drug Trial Results #USA #San_Diego #Regulus_Therapeutics #Novartis #farabursen

Акции Regulus взлетели после сообщения о приобретении компанией Novartis | Новости | GxP News Швейцарский фармгигант Novartis согласился приобрести биофармацевтическую компанию Regulus Therapeutics, которая специализируется на микроРНК-терапии для. Новости GxP News.

Акции Regulus взлетели после сообщения о приобретении к...

gxpnews.net/2025/04/akczii-regulus-v...

#Новости #Новости #фармотрасли #farabursen #Novartis #Regulus #Therapeutics #акции #сделка #Фармрынок

Result Details

Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion Regulus Therapeutics has announced its acquisition by Novartis for $7.00 per share, potentially totaling $1.7 billion with contingent rights.

Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion #USA #San_Diego #Regulus_Therapeutics #farabursen #Novartis_AG

Regulus Therapeutics Celebrates Positive Trial Results for Farabursen in ADPKD Treatment Regulus Therapeutics has announced positive results from its Phase 1b trial for Farabursen, a promising treatment for ADPKD. This breakthrough demonstrates significant progress in managing this condition.

Regulus Therapeutics Celebrates Positive Trial Results for Farabursen in ADPKD Treatment #United_States #San_Diego #Regulus_Therapeutics #farabursen #ADPKD

Regulus Therapeutics Releases Q4 2024 Financial Report and Key Developments Regulus Therapeutics Inc. recently announced its financial results for Q4 2024, highlighting progress in its groundbreaking clinical trials for ADPKD treatments.

Regulus Therapeutics Releases Q4 2024 Financial Report and Key Developments #USA #San_Diego #Regulus_Therapeutics #farabursen #ADPKD

Regulus Therapeutics Reports Promising Outcomes in ADPKD Clinical Trials with Farabursen Regulus Therapeutics reveals positive interim data from its Phase 1b trial for ADPKD treatment with farabursen, aligning with FDA for next steps.

Regulus Therapeutics Reports Promising Outcomes in ADPKD Clinical Trials with Farabursen #USA #San_Diego #Regulus_Therapeutics #farabursen #ADPKD